These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 27669301)

  • 21. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.
    Filmus J; Capurro M
    FEBS J; 2013 May; 280(10):2471-6. PubMed ID: 23305321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Highly Potent Immunotoxins Targeting the Membrane-distal N-lobe of GPC3 for Immunotherapy of Hepatocellular Carcinoma.
    Li J; Xiang L; Wang Q; Ma X; Chen X; Zhu Y; Yang Y; Huang L; He H; Xu L; Liang X; Dong S; Hu S; Li H; Feng M
    J Cancer; 2022; 13(4):1370-1384. PubMed ID: 35281879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma.
    Feng M; Gao W; Wang R; Chen W; Man YG; Figg WD; Wang XW; Dimitrov DS; Ho M
    Proc Natl Acad Sci U S A; 2013 Mar; 110(12):E1083-91. PubMed ID: 23471984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.
    Haruyama Y; Kataoka H
    World J Gastroenterol; 2016 Jan; 22(1):275-83. PubMed ID: 26755876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma.
    Fu Y; Urban DJ; Nani RR; Zhang YF; Li N; Fu H; Shah H; Gorka AP; Guha R; Chen L; Hall MD; Schnermann MJ; Ho M
    Hepatology; 2019 Aug; 70(2):563-576. PubMed ID: 30353932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of nanobodies against hepatocellular carcinoma marker glypican-3.
    Wang W; Xu C; Wang H; Jiang C
    Mol Immunol; 2021 Mar; 131():13-22. PubMed ID: 33453658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.
    Zhu AX; Gold PJ; El-Khoueiry AB; Abrams TA; Morikawa H; Ohishi N; Ohtomo T; Philip PA
    Clin Cancer Res; 2013 Feb; 19(4):920-8. PubMed ID: 23362325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling.
    Midorikawa Y; Ishikawa S; Iwanari H; Imamura T; Sakamoto H; Miyazono K; Kodama T; Makuuchi M; Aburatani H
    Int J Cancer; 2003 Feb; 103(4):455-65. PubMed ID: 12478660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Frizzled-Like Cysteine-Rich Domain in Glypican-3 Mediates Wnt Binding and Regulates Hepatocellular Carcinoma Tumor Growth in Mice.
    Li N; Wei L; Liu X; Bai H; Ye Y; Li D; Li N; Baxa U; Wang Q; Lv L; Chen Y; Feng M; Lee B; Gao W; Ho M
    Hepatology; 2019 Oct; 70(4):1231-1245. PubMed ID: 30963603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of a Glypican-3-Binding Peptide for In Vivo Non-Invasive Human Hepatocellular Carcinoma Detection.
    Qin Z; Wang J; Wang Y; Wang G; Wang X; Zhou Z; Liu G; Gao S; Zhu L
    Macromol Biosci; 2017 Apr; 17(4):. PubMed ID: 27862961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling.
    Capurro M; Martin T; Shi W; Filmus J
    J Cell Sci; 2014 Apr; 127(Pt 7):1565-75. PubMed ID: 24496449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploring Glypican-3 as a Molecular Target in Hepatocellular Carcinoma: Perspectives on Diagnosis and Precision Immunotherapy Strategies.
    Tojjari A; Hafez AH; Saeed A; Singh M; Saeed A
    Front Biosci (Landmark Ed); 2024 Jul; 29(7):268. PubMed ID: 39082348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin.
    Ho M
    BioDrugs; 2011 Oct; 25(5):275-84. PubMed ID: 21942912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma.
    Zhang YF; Ho M
    Sci Rep; 2016 Sep; 6():33878. PubMed ID: 27667400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glypican-3: a new target for cancer immunotherapy.
    Ho M; Kim H
    Eur J Cancer; 2011 Feb; 47(3):333-8. PubMed ID: 21112773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo.
    Zittermann SI; Capurro MI; Shi W; Filmus J
    Int J Cancer; 2010 Mar; 126(6):1291-301. PubMed ID: 19816934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
    Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
    Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line.
    Ruan J; Liu F; Chen X; Zhao P; Su N; Xie G; Chen J; Zheng D; Luo R
    Int J Mol Med; 2011 Oct; 28(4):497-503. PubMed ID: 21617840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The cancer specific antigen, glypican-3 (GPC3)-targeted immunotherapy].
    Sawada Y; Nakatsura T
    Nihon Rinsho; 2012 Dec; 70(12):2136-41. PubMed ID: 23259386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotoxins Immunotherapy against Hepatocellular Carcinoma: A Promising Prospect.
    Heiat M; Hashemi Yeganeh H; Alavian SM; Rezaie E
    Toxins (Basel); 2021 Oct; 13(10):. PubMed ID: 34679012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.